These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 26448614)

  • 1. Treatment of dermatomyositis with ruxolitinib.
    Fioranelli M; Roccia MG; Lotti T
    Dermatol Ther; 2016 Jul; 29(4):285. PubMed ID: 26448614
    [No Abstract]   [Full Text] [Related]  

  • 2. Remission of recalcitrant dermatomyositis treated with ruxolitinib.
    Hornung T; Janzen V; Heidgen FJ; Wolf D; Bieber T; Wenzel J
    N Engl J Med; 2014 Dec; 371(26):2537-8. PubMed ID: 25539124
    [No Abstract]   [Full Text] [Related]  

  • 3. More on remission of recalcitrant dermatomyositis treated with ruxolitinib.
    Hornung T; Wolf D; Wenzel J
    N Engl J Med; 2015 Mar; 372(13):1274. PubMed ID: 25806934
    [No Abstract]   [Full Text] [Related]  

  • 4. More on remission of recalcitrant dermatomyositis treated with ruxolitinib.
    Selva-O'Callaghan A; Trallero-Araguás E; Labrador-Horrillo M
    N Engl J Med; 2015 Mar; 372(13):1273-4. PubMed ID: 25806935
    [No Abstract]   [Full Text] [Related]  

  • 5. Remission of food allergy by the Janus kinase inhibitor ruxolitinib in mice.
    Yamaki K; Yoshino S
    Int Immunopharmacol; 2014 Feb; 18(2):217-24. PubMed ID: 24332884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Janus kinase inhibition as a potential strategy for the treatment of psoriasis: state of the art and future perspectives.
    Cassano N; Vena GA
    J Biol Regul Homeost Agents; 2012; 26(4):587-96. PubMed ID: 23241109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical Ruxolitinib for the Treatment of Alopecia Universalis.
    Craiglow BG; Tavares D; King BA
    JAMA Dermatol; 2016 Apr; 152(4):490-1. PubMed ID: 26649829
    [No Abstract]   [Full Text] [Related]  

  • 8. Ruxolitinib for refractory large granular lymphocyte leukemia.
    Moignet A; Pastoret C; Cartron G; Coppo P; Lamy T
    Am J Hematol; 2021 Oct; 96(10):E368-E370. PubMed ID: 34133042
    [No Abstract]   [Full Text] [Related]  

  • 9. Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis.
    Palandri F; Palumbo GA; Elli EM; Polverelli N; Benevolo G; Martino B; Abruzzese E; Tiribelli M; Tieghi A; Latagliata R; Cavazzini F; Bergamaschi M; Binotto G; Crugnola M; Isidori A; Caocci G; Heidel F; Pugliese N; Bosi C; Bartoletti D; Auteri G; Cattaneo D; Scaffidi L; Trawinska MM; Stella R; Ciantia F; Pane F; Cuneo A; Krampera M; Semenzato G; Lemoli RM; Iurlo A; Vianelli N; Cavo M; Breccia M; Bonifacio M
    Blood Cancer J; 2021 Jan; 11(1):4. PubMed ID: 33414394
    [No Abstract]   [Full Text] [Related]  

  • 10. Unexpected Hair Regrowth in a Patient with Longstanding Alopecia Universalis During Treatment of Recalcitrant Dermatomyositis with the Janus Kinase Inhibitor Ruxolitinib.
    Fetter T; Rios GC; Niebel D; Bieber T; Wenzel J
    Acta Derm Venereol; 2020 May; 100(10):adv00144. PubMed ID: 32285135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical management of myelofibrosis with ruxolitinib.
    Ho PJ; Marlton P; Tam C; Stevenson W; Ritchie D; Bird R; Dunlop LC; Durrant S; Ross DM
    Intern Med J; 2015 Dec; 45(12):1221-30. PubMed ID: 26648193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of bone marrow microenvironment following ruxolitinib therapy in myelofibrosis.
    Caocci G; Maccioni A; Murgia F; Perra A; Usai M; Piga M; Mascia R; La Nasa G
    Leuk Lymphoma; 2016 May; 57(5):1215-8. PubMed ID: 26308187
    [No Abstract]   [Full Text] [Related]  

  • 13. Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia: a report on 12 Danish patients.
    Bjørn ME; Holmström MO; Hasselbalch HC
    Leuk Lymphoma; 2016; 57(1):125-8. PubMed ID: 25936872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistent janus kinase-signaling in chronic lymphocytic leukemia patients on ibrutinib: Results of a phase I trial.
    Spaner DE; McCaw L; Wang G; Tsui H; Shi Y
    Cancer Med; 2019 Apr; 8(4):1540-1550. PubMed ID: 30843659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ruxolitinib for pulmonary extramedullary hematopoiesis in myelofibrosis.
    Maccaferri M; Leonardi G; Marasca R; Colaci E; Paolini A; Soci F; Forghieri F; Potenza L; Narni F; Luppi M
    Leuk Lymphoma; 2014 Sep; 55(9):2207-8. PubMed ID: 24354678
    [No Abstract]   [Full Text] [Related]  

  • 16. Improvement of bone marrow fibrosis with ruxolitinib: will this finding change our perception of the drug?
    Breccia M; Molica M; Colafigli G; Alimena G
    Expert Rev Hematol; 2015 Aug; 8(4):387-9. PubMed ID: 25915176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: A case series.
    Hansen S; Alduaij W; Biggs CM; Belga S; Luecke K; Merkeley H; Chen LYC
    Eur J Haematol; 2021 May; 106(5):654-661. PubMed ID: 33523540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Klebsiella pneumoniae primary liver abscess associated with ruxolitinib.
    Kusano Y; Terui Y; Ueda K; Hatake K
    Ann Hematol; 2016 Sep; 95(9):1561-2. PubMed ID: 27259987
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.
    Arana Yi C; Tam CS; Verstovsek S
    Future Oncol; 2015; 11(5):719-33. PubMed ID: 25757677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term Effects of the Janus Kinase 1/2 Inhibitor Ruxolitinib on Pulmonary Hypertension and the Cardiac Function in a Patient with Myelofibrosis.
    Miyawaki H; Kioka H; Sato K; Kurashige M; Ozawa T; Shibayama H; Hikoso S; Morii E; Yamauchi-Takihara K; Sakata Y
    Intern Med; 2020 Jan; 59(2):229-233. PubMed ID: 31534088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.